

# Renato De Vecchis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3897753/publications.pdf>

Version: 2024-02-01

84  
papers

607  
citations

687335

13  
h-index

794568

19  
g-index

99  
all docs

99  
docs citations

99  
times ranked

1159  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distrust of the new non-citational metrics must be overcome: how to give the appropriate value not only to citing, but also to clicking. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 109-110.	0.7	0
2	Pill-in-the-pocket therapy for paroxysmal atrial fibrillation: a revival of interest for an old approach in the area of antiarrhythmic strategies. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 121-123.	0.7	0
3	Authorship growth and self-citations: two ways for inflating the H-index in contemporary medical literature?. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 326.	1.5	1
4	Authorship growth and self-citations: a scholarly expedient that demonstrates that the use of the metrics for career decisions generates malpractice and misbehavior?. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 619-620.	0.7	0
5	Advancements in the diagnostic workup, prognostic evaluation, and treatment of takotsubo syndrome. <i>Heart Failure Reviews</i> , 2020, 25, 757-771.	3.9	11
6	A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2095218.	0.3	8
7	Alternative metrics to assess the quality and impact at the level of the individual article: how to go beyond the conventional criteria of judgment without citing a given article, but simply by "clicking" on it. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 837.	1.5	0
8	Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan. <i>Cardiology Research</i> , 2020, 11, 213-218.	1.1	12
9	Favorable Effects of Sacubitril/Valsartan on the Peak Atrial Longitudinal Strain in Patients With Chronic Heart Failure and a History of One or More Episodes of Atrial Fibrillation: A Retrospective Cohort Study. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 100-107.	1.2	20
10	Thyrotoxic dilated cardiomyopathy: personal experience and case collection from the literature. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.5	5
11	Problemas Relacionados À Trombocitopenia em Pacientes com Fibrilação Atrial Concomitante que Necessitam de Prevenção Antitrombótica: Um Estudo de Coorte Retrospectivo. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 717-718.	0.8	0
12	Is sacubitril/valsartan safe for treatment of hypertension at any age?. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 49.	1.5	1
13	High Prevalence of Proarrhythmic Events in Patients With History of Atrial Fibrillation Undergoing a Rhythm Control Strategy: A Retrospective Study. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 345-352.	1.2	6
14	Similar outcome of heart failure with reduced EF patients with and without atrial fibrillation: considerations from the ESC Heart Failure Long-Term Registry. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.6	0
15	Is an elevated burden of antiarrhythmic drug (AAD) side-effects the unavoidable price to be traded for a durable suppression of AF relapses in ablated patients? The weaknesses and risks of the AAD suppression algorithm used by current models of AF secondary prevention after catheter ablation. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 873-874.	1.9	0
16	Promising effects of moderate-dose corticosteroid therapy in the blanking period for prevention of atrial fibrillation (AF) recurrences in patients undergoing AF ablation. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1179-1180.	1.9	2
17	HFREF Patients and Atrial Fibrillation: Time to Reconsider the Appropriateness of the Atrial Fibrillation Ablation in This Patient Subset?. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 383-384.	2.6	0
18	Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. <i>Heart Failure Reviews</i> , 2019, 24, 521-533.	3.9	23

#	ARTICLE	IF	CITATIONS
19	Atrial mechanical hypofunction after electrical cardioversion of persistent or long-lasting persistent atrial fibrillation: a retrospective cohort study. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.6	0
20	Conversion to and maintenance of sinus rhythm do not yield a significant increase in stroke-volume in HFREF patients, whose heart works on the flat branch of Frank's Starling curve, thereby making the retrieval of the atrial mechanical contribution in this subset a substantially futile choice. <i>European Heart Journal</i> , 2019, 40, 3651-3652.	2.2	2
21	In heart failure with reduced ejection fraction patients' left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blockers. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 857-858.	1.5	2
22	Long-term antiarrhythmic drug treatment after atrial fibrillation ablation: does a too obstinate rhythm control strategy bring serious risk of proarrhythmia to ablated patients?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 117-118.	3.0	3
23	CABANA trial: disappointing results?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 57-57.	3.0	1
24	Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction. <i>Herz</i> , 2019, 44, 425-432.	1.1	24
25	Cognitive performance of patients with chronic heart failure on sacubitril/valsartan. <i>Herz</i> , 2019, 44, 534-540.	1.1	16
26	In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization. <i>Herz</i> , 2019, 44, 651-658.	1.1	7
27	A Case of Fatal Intestinal Infarct Preceded by Recurrent Ischaemic Colitis due to the Enterotoxic Effect of Sodium Polystyrene Sulfonate. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 8, 001973.	0.4	0
28	Anti-Hypertensive Effect of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials. <i>Cardiology Research</i> , 2019, 10, 24-33.	1.1	16
29	Rate Control Yields Better Clinical Outcomes Over a Median Follow-Up of 20 Months Compared to Rhythm Control Strategy in Patients With a History of Atrial Fibrillation: A Retrospective Cohort Study. <i>Cardiology Research</i> , 2019, 10, 98-105.	1.1	3
30	Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study. <i>Cardiology Research</i> , 2019, 10, 293-302.	1.1	13
31	Antihypertensive effect of sacubitril/valsartan: a meta-analysis. <i>Minerva Cardioangiologica</i> , 2019, 67, 214-222.	1.2	10
32	Ablation, rate or rhythm control strategies for patients with atrial fibrillation: how do they affect mid-term clinical outcomes?. <i>Minerva Cardioangiologica</i> , 2019, 67, 272-279.	1.2	1
33	Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction. <i>Minerva Cardioangiologica</i> , 2019, 67, 456-463.	1.2	11
34	Secondary Prevention of Nonvalvular Atrial Fibrillation: A Retrospective Cohort Study. <i>Cardiology Research</i> , 2019, 10, 223-229.	1.1	2
35	Addressing the Challenge of Atrial Fibrillation Management: How to Differentiate the Approach Depending on Left Ventricular Ejection Fraction. <i>Cardiology Research</i> , 2019, 10, 253-254.	1.1	0
36	Is Left Atrial Appendage Occlusion Really Efficacious in Avoiding Administering Anticoagulant Drugs for the Prevention of Cardioembolic Events in Patients With Atrial Fibrillation?. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 664-665.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Secondary Prevention of Atrial Fibrillation: Is It Worth Doing?. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 309.	1.2	0
38	Network meta-analysis: a new analysis tool of the experimental evidence. <i>Minerva Medica</i> , 2019, 110, 173-175.	0.9	0
39	Effects of dronedarone on all-cause mortality and on cardiovascular events in patients treated for atrial fibrillation: a meta-analysis of RCTs. <i>Minerva Cardioangiologica</i> , 2019, 67, 163-171.	1.2	2
40	Diuretic dosing in heart failure: more data are needed. <i>ESC Heart Failure</i> , 2018, 5, 649-650.	3.1	3
41	Use of newly designed graphs for depicting network meta-analyses. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 681-683.	1.5	0
42	Malignant Ventricular Arrhythmias Resulting From Drug-Induced QTc Prolongation: A Retrospective Study. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 593-600.	1.2	2
43	Acquired drug-induced long QTc: new insights coming from a retrospective study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1645-1651.	1.9	5
44	Illustrating the Sense of a Network Meta-Analysis by Means of Dedicated Plots: A Way for Making It Conceptually Easier and More Immediately Understandable. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 732-735.	1.2	2
45	Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. <i>Minerva Cardiology and Angiology</i> , 2018, 66, 349-359.	0.7	6
46	Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis. <i>Minerva Cardioangiologica</i> , 2018, 66, 659-670.	1.2	8
47	A New Approach for Hypertension: the Case of Sacubitril/Valsartan Experienced in Randomized Controlled Trials That Selectively Restrict Its Use to the Hypertension of the Elderly. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 853-854.	1.2	3
48	Transcatheter closure of PFO as secondary prevention of cryptogenic stroke. <i>Herz</i> , 2017, 42, 45-50.	1.1	7
49	Comorbidity "depression" in heart failure " Potential target of patient education and self-management. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 48.	1.7	8
50	Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. <i>Interventional Medicine &amp; Applied Science</i> , 2017, 9, 123-135.	0.2	2
51	Prognostic value of clinical, echocardiographic and angiographic indicators in patients with large anterior ST-segment elevation myocardial infarction as a first acute coronary event. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 946-953.	1.5	3
52	Vasopressin receptor antagonists in patients with chronic heart failure. <i>Herz</i> , 2017, 42, 492-497.	1.1	4
53	Platypnea"orthodeoxia syndrome. <i>Herz</i> , 2017, 42, 384-389.	1.1	9
54	Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 266-272.	1.2	8

#	ARTICLE	IF	CITATIONS
55	Natriuretic peptide-guided versus clinically guided therapy for chronic heart failure: careful expert clinical management can remove need for biomarker-tailored dosing adjustment. <i>Journal of Thoracic Disease</i> , 2017, 9, 4137-4140.	1.4	0
56	The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 130-142.	1.2	5
57	Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 488-498.	1.2	28
58	Thiazides and Osteoporotic Spinal Fractures: A Suspected Linkage Investigated by Means of a Two-Center, Case-Control Study. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 943-949.	1.2	6
59	Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction—results of a meta-analysis of randomized controlled trials. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 272-287.	1.7	3
60	Ranolazine and TDM1 treatment: Cardioprotective effects in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23102-e23102.	1.6	0
61	Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials. <i>Minerva Cardiology and Angiology</i> , 2017, 65, 427-442.	0.7	1
62	Effects of Hyponatremia Normalization on the Short-Term Mortality and Rehospitalizations in Patients with Recent Acute Decompensated Heart Failure: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2016, 5, 92.	2.4	15
63	Platypnea—Orthodeoxia Syndrome: Multiple Pathophysiological Interpretations of a Clinical Picture Primarily Consisting of Orthostatic Dyspnea. <i>Journal of Clinical Medicine</i> , 2016, 5, 85.	2.4	24
64	Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 153-161.	1.2	24
65	Effects of limiting fluid intake on clinical and laboratory outcomes in patients with heart failure. <i>Herz</i> , 2016, 41, 63-75.	1.1	21
66	Measuring B-Type Natriuretic Peptide From Capillary Blood or Venous Sample: Is It the Same?. <i>Cardiology Research</i> , 2016, 7, 51-58.	1.1	6
67	Unresolved or Contradictory Issues About Management of Patients With Patent Foramen Ovale and Previous Cryptogenic Stroke: Additional Randomized Controlled Trials Are Eagerly Awaited. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 361-366.	1.2	4
68	Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 449-460.	1.2	7
69	Estimating Right Atrial Pressure Using Ultrasounds: An Old Issue Revisited With New Methods. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 569-574.	1.2	17
70	Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 737-742.	1.2	8
71	The MacNew Questionnaire Is a Helpful Tool for Predicting Unplanned Hospital Readmissions After Coronary Revascularization. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 210-214.	1.2	1
72	Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. <i>Anatolian Journal of Cardiology</i> , 2015, 16, 2-9.	0.9	29

#	ARTICLE	IF	CITATIONS
73	The Relation Between Global Longitudinal Strain and Serum Natriuretic Peptide Is More Strict Than That Found Between the Latter and Left Ventricular Ejection Fraction: A Retrospective Study in Chronic Heart Failure. <i>Journal of Clinical Medicine Research</i> , 2015, 7, 979-988.	1.2	10
74	Inferior vena cava and hemodynamic congestion. <i>Research in Cardiovascular Medicine</i> , 2015, 4, 3.	0.1	17
75	Cardiorenal syndrome type 2: from diagnosis to&nbsp;optimal management. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 949.	2.0	19
76	B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 122-134.	1.5	38
77	Statin use for nonrheumatic calcific aortic valve stenosis. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 559-567.	1.5	10
78	Ultrasound evaluation of the inferior vena cava collapsibility index in congestive heart failure patients treated with intravenous diuretics: new insights about its relationship with renal function: An observational study. <i>Anatolian Journal of Cardiology</i> , 2012, 12, 391-400.	0.4	9
79	Colapsibilidade da Veia Cava Inferior e sinais e sintomas de insuficiÃªncia cardÃaca: novos insights e possÃveis associaÃ§Ães. <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 98, 544-552.	0.8	4
80	The Relation Between Carotid Atherosclerotic Plaques and Ischemic Stroke Is Critically Conditioned by the Role of Arterial Hypertension as an Effect Modifier. <i>Canadian Journal of Cardiology</i> , 2011, 27, 152-158.	1.7	2
81	Terapia com inibidor da ECA com dosagens relativamente altas e risco de agravamento renal na insuficiÃªncia cardÃaca crÃnica. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 97, 507-516.	0.8	2
82	Reply: intravenous loop diuretics versus isolated ultrafiltration for chronic congestive heart failure: competition or integration?. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 3-4.	1.5	0
83	Intimaâ€media thickness of internal carotid arteries and total carotid plaque area: two surrogate endpoints of which the former has to be considered a weaker putative measure of subclinical atherosclerosis compared with the latter. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 325.	1.5	4
84	Unloading therapy by intravenous diuretic in chronic heart failure: a double-edged weapon?. <i>Journal of Cardiovascular Medicine</i> , 2010, Publish Ahead of Print, 571-4.	1.5	8